Telegram RegisterThe public register of Telegram
Telegram profile photo for Clinical Trials | Medications

Channel

Clinical Trials | Medications

@clinical_trials

On this record: Topic · Growth · Engagement · Reactions · Posts · Telegram's recommendations · Cite this entry

1,022subscribers

+32 since we began measuring on 16 September 2026

Risers and fallers across the register · movement among entries of 1,000–3,162.

Register entry

Telegram ID-1001549705298
TypeChannel
Username@clinical_trials
CreatedBetween 1 August 2021 and 28 February 2023 — estimated from Telegram’s id allocation, not measured. How this range is calculated.
First recorded16 September 2026
Last confirmed live7 November 2026
Measurements held11
Confirmed unchanged2 times, most recently 7 November 2026
On Telegramt.me/clinical_trials

Topic

Health & wellness — a classification, not a measurement. An on-box language model (Qwen3.6-35B-A3B-FP8, prompt version 1) read this channel’s own recent posts on 3 October 2026 and assigned it the closest of 31 fixed categories, at 96% confidence. This is a model’s judgement about what the channel is likely to be about, not a fact this register measured the way a subscriber count or a view count is measured — it can be revised on a later pass, and it carries no weight anywhere else on this page. How this classification works, and the other topics.

Growth

9901,0221,00616 September 2026 — 990 subscribers16 September 2026 — 990 subscribers18 September 2026 — 998 subscribers2 October 2026 — 999 subscribers13 October 2026 — 1,002 subscribers15 October 2026 — 1,004 subscribers22 October 2026 — 1,011 subscribers25 October 2026 — 1,012 subscribers28 October 2026 — 1,017 subscribers31 October 2026 — 1,019 subscribers4 November 2026 — 1,022 subscribers16 September 20264 November 2026
11 measurements spanning 49 days, net +32. Dots are measurements; the straight line between them is drawn to join them, not to claim we know the path taken in between — snapshots are recorded only when a count changes, so gaps mean “no change observed”, never “interpolated”. The vertical axis spans 985–1,027 and does not start at zero.
Measurement log — every subscribers count we have recorded
Measured (UTC)SubscribersChange
4 Nov 2026, 04:591,022+3
31 Oct 2026, 18:191,019+2
28 Oct 2026, 18:471,017+5
25 Oct 2026, 22:201,012+1
22 Oct 2026, 18:071,011+7
15 Oct 2026, 22:451,004+2
13 Oct 2026, 06:551,002+3
2 Oct 2026, 23:38999+1
18 Sept 2026, 16:16998+8
16 Sept 2026, 14:22990no change
16 Sept 2026, 13:47990first reading

Engagement

20 posts held, back to 8 September 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 1 page of Telegram’s post history, 20 posts per page.

Nothing published in the last 30 days. ERR and ER are rolling 30-day measures, so there is nothing to compute — we hold 20 posts for this entry, the most recent from 16 September 2026. An engagement rate over an empty window would be a number about nothing.

Reaction mix

1 reaction across 1 post, in 1 kind.

Every reaction kind recorded on the sample, most used first
ReactionCountShareShare, drawn
❤1100.0%

No sentiment is inferred, and none should be read in. This table is ordered by count and by nothing else. Emoji do not carry stable meaning across languages or communities — 🙏 is thanks in one channel and mourning in another — so we publish which ones were pressed and how often, and pass no judgement on what an audience meant by them.

Precision. Telegram publishes reaction counts per emoji and short-forms each one — 4.34K, 1.2M — so any single kind at or above 1,000 reaches us at three significant figures, and only counts below 1,000 are exact. The shares above are ratios of those figures and carry the same error. This is also why the total here can differ slightly from a reaction total printed elsewhere on the page: both are sums of the same rounded parts, taken over samples with different edges.

Coverage. Reactions were read on 1 of the 20 sampled posts in this sample. Summed by Telegram’s own count on each post — not by adding up the per-emoji breakdown above — those same posts carry 1 reactions in total: the kind of figure the paragraph above means by “a reaction total printed elsewhere on the page”.

Measured over the 20 most recent posts we hold, published 8 September 2026 to 16 September 2026, using the newest reading held for each. Telegram Stars are excluded: they are a payment, not a reaction, and they have their own section.

Recent posts

16 Sept 2026, 07:11 UTC15 views1 reactionsread 16 September 2026

From 7,000 drugs to one active against resistant strains: AI advances pneumonia drug repurposing Streptococcus pneumoniae is a bacterial pathogen that causes life-threatening infections, including pneumonia and meningitis. These infections are commonly treated with antibiotics, but antibiotics are becoming less effective against S. pneumoniae over time because of changes in the pathogen that cause drug resistance. T…

❤1

15 Sept 2026, 19:04 UTC27 viewsread 16 September 2026

Drug improves sexual function for patients with depression, study finds Patients with major depressive disorder (MDD) and an inadequate response to standard antidepressants who received add-on treatment with the drug lumateperone had significantly improved sexual function, according to a new study led by a University of Virginia School of Medicine researcher. https://medicalxpress.com/news/2026-09-drug-sexual-funct…

15 Sept 2026, 18:22 UTC22 viewsread 16 September 2026

Experimental drug shows potential for hard-to-treat heart disease An experimental drug has been shown to improve symptoms, exercise capacity and heart failure status in patients with an inherited heart disease, according to a pair of newly published studies. https://medicalxpress.com/news/2026-09-experimental-drug-potential-hard-heart.html

14 Sept 2026, 18:43 UTC36 viewsread 16 September 2026

Common epilepsy drug levetiracetam presents potential clot risk for patients taking blood thinners Researchers from the University of Liverpool and the University of Zurich have identified a potential safety consideration involving levetiracetam, one of the world's most commonly prescribed antiseizure medications. https://medicalxpress.com/news/2026-09-common-epilepsy-drug-levetiracetam-potential.html

14 Sept 2026, 14:14 UTC39 viewsread 16 September 2026

Common antibiotic linked to possible higher death risk Cefepime is a fourth-generation antibiotic widely used to treat serious bacterial infections and febrile neutropenia—a fever in patients with abnormally low white blood cell counts. Unlike many antibiotics that are falling prey to antimicrobial resistance, cefepime is relatively stable against AmpC β-lactamases, giving it an advantage against bacteria that produ…

13 Sept 2026, 22:30 UTC38 viewsread 16 September 2026

New US Medicare pricing policies could reshape global pharmaceutical markets A new modeling study published in The Lancet suggests that U.S. Medicare's new "Most-Favored-Nation" pricing policy, which ties what Medicare pays for medicines to prices charged in other high-income countries, could push pharmaceutical manufacturers to raise prices or delay launches. For about three in four medicines studied, the resulting…

13 Sept 2026, 21:01 UTC32 viewsread 16 September 2026

Masked antibodies may open intracellular treatment route for Parkinson's disease Over the past few decades, antibody-based therapies have revolutionized modern medicine and are now widely used to treat cancer, autoimmune diseases, inflammatory disorders and even infectious diseases. Despite their success, however, antibodies have a significant limitation: They struggle to penetrate cells and are therefore largely li…

12 Sept 2026, 15:24 UTC45 viewsread 16 September 2026

AI virtual cell uses protein dynamics to predict personalized breast cancer treatments Not all cancer cells are the same, and neither are their responses to drugs. Finding the right drug for the right cancer cell is a long battle in drug development and in designing effective treatments. A new AI tool called ProteinTalks makes this task easier by accurately predicting whether a drug will be effective against a cance…

12 Sept 2026, 00:03 UTC39 viewsread 16 September 2026

Promising broad-spectrum antiviral candidate against enteroviruses identified Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have identified a promising antiviral compound that can inhibit a range of enteroviruses, including Enterovirus D68 (EV-D68), an emerging respiratory virus linked to severe respiratory illness and acute flaccid myelitis, a condition that …

11 Sept 2026, 09:00 UTC47 viewsread 16 September 2026

Chemotherapy alters 'Darwinian battleground' in our bodies Cancer treatments, including chemotherapy and radiation therapy, give a growth advantage to cells with particular genetic changes in healthy tissue, new research finds. https://medicalxpress.com/news/2026-09-chemotherapy-darwinian-battleground-bodies.html

10 Sept 2026, 22:34 UTC40 viewsread 16 September 2026

Potentially harmful drug combinations prescribed to older adults identified A new Ontario-wide study reveals that common medications, from statins to iron supplements, are quietly setting off prescribing cascades that leave older adults unknowingly taking drugs to treat side effects of other drugs. https://medicalxpress.com/news/2026-09-potentially-drug-combinations-older-adults.html

10 Sept 2026, 14:22 UTC35 viewsread 16 September 2026

Blood protein analysis suggests a lung disease drug could be fighting aging at the same time In 2025, Insilico Medicine developed an experimental drug called rentosertib as a treatment for idiopathic pulmonary fibrosis, a severe age-related lung disease. The drug works by inhibiting the protein TNIK, which is involved in both scar tissue formation in the lungs and fundamental hallmarks of biological aging. The resea…

Showing the 12 most recent of 20 posts we hold for @clinical_trials. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.

Appears in Telegram’s recommendations for other channels

The reverse of the list above, and a different kind of signal. This does not require this channel to have ever been asked about directly — each row below is a channel we DID ask Telegram about, whose Telegram-generated list happened to include this one. A channel can appear here with an empty list above it, because being named by someone else’s query is independent of having been queried itself.

Pharma Jobs Daily – Pharmastuff.org
@todaypharmajob · 23,334
Telegram ranks this channel #29 of 54 here — alongside 53 others — read 18 September 2026
Scholarships opportunities
@freescholarshipsworldwide · 24,521
Telegram ranks this channel #55 of 62 here — alongside 61 others — read 16 September 2026

This channel appears in 2 seed channels' Telegram-generated recommendation lists in total. Each is Telegram’s list for THAT channel, not this one — see how this is measured.

Cite this entry

A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 4 November 2026 — this entry's latest reading, not the date you are reading this.

“Clinical Trials | Medications” (@clinical_trials), 1,022 subscribers as measured 4 November 2026. Telegram Register, tgregister.com/channel/clinical_trials.

Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.